Can Personalized Neoantigens Raise the T Cell Bar?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33064984.
- Also identified by DOI 10.1016/j.cell.2020.09.053 and PMC identifier 9485863.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ott et al. report the results of a phase 1B study in which a personalized neoantigen vaccine was combined with programmed death receptor-1 blockade in patients with advanced cancers. The study provides a framework for combinatorial vaccine therapies that could mount robust T cell responses, enhance tumor killing, and provide clinical benefit.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Melanoma
- Urinary Bladder Neoplasms